Trials / Completed
CompletedNCT00818337
Aspirin Responsiveness in Women at Risk for Cardiac Events
Aspirin Responsiveness in Women at Risk for Cardiac Events: A Pilot Study.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Creighton University · Academic / Other
- Sex
- Female
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be measured with the VerifyNow device (Accumetrics; San Diego, CA). Those women identified as biologically resistant will be switched to aspirin 325 mg for 14 days and then re-tested for aspirin responsiveness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin | Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2009-01-07
- Last updated
- 2012-12-04
- Results posted
- 2012-12-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00818337. Inclusion in this directory is not an endorsement.